Professor Robert Bristow

Robert Bristow, Director, MCRC and CRUK Manchester Centre

Headshot of Professor Rob Bristow

Director, Manchester Cancer Research Centre,

Director, CRUK Manchester Centre

Senior Group Leader, Translational Oncogenomics, CRUK Manchester Institute

Chief Academic Officer & Honorary Consultant, The Christie NHS Foundation Trust

Cancer Domain Lead and University Professor of Cancer Studies, The University of Manchester

 

Robert Bristow completed his PhD in Medical Biophysics and Residency in Radiation Oncology at the University of Toronto with post-graduate fellowships at Erasmus University Rotterdam, MD Anderson Cancr Centre and Massachusetts General Hospial. He held positions as Professor and Clinician Scientist in Genito-Urinary cancers at the Princess Margaret Cancer Centre in Toronto during 1999-2017. Seminal contributions include his pioneering work on the prostate cancer genome and tumour microenvironment hypoxic tumour cell characterisation by understanding role of hypoxia in driving genetic instability and the changes in sporadic and hereditary (e.g. BRCA2) prostate cancer genomes during cancer aggression. Co-leading the Canadian ICGC prostate cancer team, he found that a significant proportion of prostate cancers harbour copy number alterations and large-scale genomic rearrangements, that when combined with sub-regions of hypoxia, are co-drivers that lead to adverse prognosis. Bristow joined the University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy for Manchester with a cancer team science approach. He serves on a number of international Scientific Advisory Boards and had more than 300 published papers. He is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004, an ESTRO Honorary Fellow in 2011 and a Fellow of the Academy of Sciences (UK) in 2019. In 2021, he was awarded the Weiss medal (Association for Radiation Research) for distinguished contributions to radiation science.

 

EA: Caroline Stone | caroline.stone@manchester.ac.uk

 

Professor Robert Bristow joined the University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy for Manchester with a cancer team science approach. The MCRC is a unique partnership between Cancer Research UK, The University of Manchester and the Christie NHS Foundation Trust.

 

His primary research interests are in tumour hypoxia, DNA damage signalling and repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions.

 

Professor Bristow is currently a senior group leader in Translational Oncogenomics at the CRUK Manchester Institute and was the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE).

 

He has served on a number of senior Scientific Advisory Boards and committees for: Prostate Cancer Foundation (USA), the MOVEMBER Foundation, the American Association for Cancer Research (AACR), the German Cancer Centre, Tuebingen Comprehensive Cancer Centre, NKI Amsterdam, the Danish Cancer Society and sits on the Scientific Executive Board for Cancer Research UK (CRUK). He has over 280 published papers and book chapters and is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004, an ESTRO Honorary Fellow in 2011 and a Fellow of the Academy of Sciences (UK) in 2019.